Abstract:Alzheimer's disease (AD) is a severe neurodegenerative disorder of the brain that manifests as dementia, disorientation, difficulty in speech, and progressive cognitive and behavioral impairment. The emerging therapeutic approach to AD management is the inhibition of beta-site APP cleaving enzyme-1 (BACE1), known to be one of the two aspartyl proteases that cleave beta-amyloid precursor protein (APP). Studies confirmed the association of high BACE1 activity with the proficiency in the formation of beta-amyloid-containing neurotic plaques, the characteristics of AD. Only a few FDA-approved BACE1 inhibitors are available in the market, but their adverse off-target effects limit their usage. In this paper, we have used both ligand-based and target-based approaches for drug design. The QSAR study entails creating a multivariate GA-MLR (Genetic Algorithm-Multilinear Regression) model using 552 molecules with acceptable statistical performance (R-2 = 0.82, Q(loo)(2) = 0.81). According to the QSAR study, the activity has a strong link with various atoms such as aromatic carbons and ring Sulfur, acceptor atoms, sp2-hybridized oxygen, etc. Following that, a database of 26,467 food compounds was primarily used for QSAR-based virtual screening accompanied by the application of the Lipinski rule of five; the elimination of duplicates, salts, and metal derivatives resulted in a truncated dataset of 8,453 molecules. The molecular descriptor was calculated and a well-validated 6-parametric version of the QSAR model was used to predict the bioactivity of the 8,453 food compounds. Following this, the food compounds whose predicted activity (pKi) was observed above 7.0 M were further docked into the BACE1 receptor which gave rise to the Identification of 4-(3,4-Dihydroxyphenyl)-2-hydroxy-1H-phenalen-1-one (PubChem I.D: 4468; Food I.D: FDB017657) as a hit molecule (Binding Affinity = -8.9 kcal/mol, pKi = 7.97 nM, Ki = 10.715 M). Furthermore, molecular dynamics simulation for 150 ns and molecular mechanics generalized born and surface area (MMGBSA) study aided in identifying structural motifs involved in interactions with the BACE1 enzyme. Molecular docking and QSAR yielded complementary and congruent results. The validated analyses can be used to improve a drug/lead candidate's inhibitory efficacy against the BACE1. Thus, our approach is expected to widen the field of study of repurposing nutraceuticals into neuroprotective as well as anti-cancer and anti-viral therapeutic interventions.

DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells

The BACE1-Specific DNA Aptamer A1 Rescues Amyloid-β Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

BACE1 Aptamer-Modified Tetrahedral Framework Nucleic Acid to Treat Alzheimer's Disease in an APP-PS1 Animal Model

The Novel Amyloid-Beta Peptide Aptamer Inhibits Intracellular Amyloid-Beta Peptide Toxicity

Development of DNA Aptamer As a Β-Amyloid Aggregation Inhibitor.

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

Discovery of Novel, Potent BACE Inhibitors with Central Activity for the Treatment of Alzheimer's Disease

Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer's disease

Lys203 and Lys382 Are Essential for the Proteasomal Degradation of BACE1

Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease

Computational identification of promising therapeutics via BACE1 Targeting: Implications for Alzheimer's disease

Identification Of Novel Bace1 Inhibitors By Combination Of Pharmacophore Modeling, Structure-Based Design And In Vitro Assay

Functional Selection of Tau Oligomerization‐Inhibiting Aptamers

In Silico Design of BACE1 Inhibitor for Alzheimer's Disease by Traditional Chinese Medicine.

Construction of a DNA Nanoassembly Based on Spatially Ordered Recognition Elements for Inhibiting β-Amyloid Aggregation

BACE1 RNA interference improves spatial memory and attenuates Aβ burden in a streptozotocin-induced tau hyperphosphorylated rat model.

A Self-Destructive Nanosweeper That Captures And Clears Amyloid Beta-Peptides

Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance

Revealing the Binding Mechanism of BACE1 Inhibitors Through Molecular Dynamics Simulations.

Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease